Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Open accessThe DOI matches its Crossref record; 28 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In patients with acute myeloid leukemia (AML) a combination of methods must be used to classify the disease, make therapeutic decisions, and determine the prognosis. However, this combined approach provides correct therapeutic and prognostic information in only 50 percent of cases. METHODS: We determined the gene-expression profiles in samples of peripheral blood or bone marrow from 285 patients with AML using Affymetrix U133A GeneChips containing approximately 13,000 unique genes or expression-signature tags. Data analyses were carried out with Omniviz, significance analysis of microarrays, and prediction analysis of microarrays software. Statistical analyses were performed to determine the prognostic significance of cases of AML with specific molecular signatures. RESULTS: Unsupervised cluster analyses identified 16 groups of patients with AML on the basis of molecular signatures. We identified the genes that defined these clusters and determined the minimal numbers of genes needed to identify prognostically important clusters with a high degree of accuracy. The clustering was driven by the presence of chromosomal lesions (e.g., t(8;21), t(15;17), and inv(16)), particular genetic mutations (CEBPA), and abnormal oncogene expression (EVI1). We identified several novel clusters, some consisting of specimens with normal karyotypes. A unique cluster with a distinctive gene-expression signature included cases of AML with a poor treatment outcome. CONCLUSIONS: Gene-expression profiling allows a comprehensive classification of AML that includes previously identified genetically defined subgroups and a novel cluster with an adverse prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“These observations were extended and recapitulated in analyses of public gene expression data (figure S5)(35–40).”
From CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors (2012) · cites this paper as [37]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These observations were extended and recapitulated in analyses of public gene expression data (figure S5)(35–40).”
From CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors (2012) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F., Ben Miled, S., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,803
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
Diagnosis of multiple cancer types by shrunken centroids of gene expression
Tibshirani, R., Hastie, T., Narasimhan, B., & Chu, G. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082099299 · Cited by 2,930
Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,655
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
Armstrong, S. A., Staunton, J. E., Silverman, L. B., Pieters, R., den Boer, M. L., Minden, M. D., Sallan, S. E., Lander, E. S., Golub, T. R., & Korsmeyer, S. J. (2002) · Nature Genetics · doi:10.1038/ng765 · Cited by 1,723 · cited 2×
“(%) <35 yr 35–60 yr ≥60 yr 76 (27) 177 (62) 32 (11)”
BackgroundSlovak, M. L., Kopecky, K. J., Cassileth, P. A., Harrington, D. H., Theil, K. S., Mohamed, A., Paietta, E., Willman, C. L., Head, D. R., Rowe, J. M., et al. (2000) · Blood · doi:10.1182/blood.v96.13.4075 · Cited by 1,601
Byrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-03-0772 · Cited by 1,597
The roles of FLT3 in hematopoiesis and leukemia
Gilliland, D. G., & Griffin, J. D. (2002) · Blood · doi:10.1182/blood-2002-02-0492 · Cited by 1,558 · cited 2×
“(%)* t(15;17) t(8;21) inv(16)/t(16;16) +8 +11 +21 ¡5 ¡5(q) ¡7 ¡7(q) 3q t(6;9) t(9;22) t(11q23) Complex karyotype (>3 chromosomal abnormalities) Other abnormal karyotypes Normal karyotype Not determined 18 (6) 22 (8) 19 (7) 26 (9) 7 (2) 2 (1) 3 (1) 1 (<1) 13 (5) 7 (2) 6 (2) 4 (1) 2 (1) 19 (7) 11 (4) 60 (21) 119 (42) 10…”
Research works printed but not linked: 1
- 17. Ossenkoppele GJ, Graveland WJ, Sonneveld P, et al. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML. Blood (in press).
Cited by
Items 401–500 of 1,000
Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia
Kühnl, A., Valk, P. J. M., Sanders, M. A., Ivey, A., Hills, R. K., Mills, K., Gale, R. E., Kaiser, M., Dillon, R. J., Joannides, M., et al. (2015) · Blood · doi:10.1182/blood-2014-12-613703 · Cited by 52
Self-citationLiang, K. L., Rishi, L., & Keeshan, K. (2013) · Blood · doi:10.1182/blood-2012-12-471300 · Cited by 50
Maury, E., & Hashizume, R. (2017) · Epigenetics · doi:10.1080/15592294.2016.1278095 · Cited by 52
“Of interest, this compound has a therapeutic potential for T-ALL, which can be driven by oncogenic activation of NOTCH1 signaling, loss-of-function mutations and deletion of the EZH2 and SUZ12 genes, and in which JMJD3 is more highly expressed compared with other types of leukemia.(81,113,114) Indeed, treatment of T-A…”
ResultYoshino, S., Yokoyama, T., Sunami, Y., Takahara, T., Nakamura, A., Yamazaki, Y., Tsutsumi, S., Aburatani, H., & Nakamura, T. (2020) · Blood · doi:10.1182/blood.2019004586 · Cited by 58
Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer
Rubin, M. A., & Chinnaiyan, A. M. (2006) · Laboratory Investigation · doi:10.1038/labinvest.3700477 · Cited by 54
Prognostic factors in acute myeloid leukemia
Avivi, I. M., & Rowe, J. M. (2004) · Current Opinion in Hematology · doi:10.1097/01.moh.0000148760.15412.df · Cited by 50
Tetrahydrogestrinone induces a genomic signature typical of a potent anabolic steroid
Labrie, F., Luu-The, V., Calvo, E. L., Martel, C., Cloutier, J., Gauthier, S., Belleau, P., Morissette, J., Lévesque, M.-H., & Labrie, C. (2005) · Journal of Endocrinology · doi:10.1677/joe.1.05997 · Cited by 52
“…by the capability to divide adult acute myeloid leukemia into subgroups having different responses to specific treatments (Bullinger et al. 2004, Valk et al. 2004), thus permitting the choice of the best treatment for each category of cancer while avoiding the serious side effects of…”
BackgroundMethodReprogramming acute myeloid leukemia into sensitivity for retinoic-acid-driven differentiation
van Gils, N., Verhagen, H. J. M. P., & Smit, L. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.04.007 · Cited by 49
Development of macrophages of cyprinid fish
Hanington, P. C., Tam, J., Katzenback, B. A., Hitchen, S. J., Barreda, D. R., & Belosevic, M. (2008) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2008.11.004 · Cited by 53
“1, and AML-1 [205–208].”
Review: genetic models of acute myeloid leukaemia
McCormack, E., Bruserud, Ø., & Gjertsen, B. T. (2008) · Oncogene · doi:10.1038/onc.2008.16 · Cited by 57
“Subsequently, distinct translocations have been linked to individual subtypes of leukaemia and are associated with particular stages of disease pathogenesis (Bullinger et al., 2004; Valk et al., 2004) or prognostic outcomes (Grimwade et al.”
BackgroundOncogenic roles of PRL‐3 in FLT3‐ITD induced acute myeloid leukaemia
Park, J. E., Yuen, H. F., Zhou, J. B., Al-Aidaroos, A. Q., Guo, K., Valk, P. J. M., Zhang, S., Chng, W. J., Hong, C. W., Mills, K., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202183 · Cited by 50
“…analyzed: (i) Our unpublished dataset (Cohort 1), analysed on Affymetrix U133Plus2 arrays from Belfast, UK; (ii) GEO ‐ accessible GSE1159 dataset (Valk et al, 2004); (iii) GEO ‐ accessible GSE6891 dataset (Verhaak et al, 2009); (iv) GEO ‐ accessible GSE15434 dataset (Kohlmann et al, 2010) and…”
Self-citationTranscriptome of blood cells as a reservoir of cardiovascular biomarkers
Devaux, Y. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.11.005 · Cited by 49
Ockenhouse, C. F., Bernstein, W. B., Wang, Z., & Vahey, M. (2005) · The Journal of Infectious Diseases · doi:10.1086/430321 · Cited by 52
A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia
Khandanpour, C., Thiede, C., Valk, P. J. M., Sharif‐Askari, E., Nückel, H., Lohmann, D. R., Horsthemke, B., Siffert, W., Neubauer, A., Grzeschik, K., et al. (2010) · Blood · doi:10.1182/blood-2009-08-239822 · Cited by 58
Self-citationWunderlich, M., Krejci, O., Wei, J.-P., & Mulloy, J. C. (2006) · Blood · doi:10.1182/blood-2005-12-012773 · Cited by 51
Reme, T. X., Hose, D., Vos, J. D., Vassal, A., Poulain, P.-O., Pantesco, V., Goldschmidt, H., & Klein, B. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-16 · Cited by 49
Lutherborrow, M. A., Bryant, A. J., Jayaswal, V., Agapiou, D., Palma, C. A., Yang, J. Y. H., & Ma, D. D. F. (2010) · American Journal of Hematology · doi:10.1002/ajh.21864 · Cited by 49
“We also reanalyzed a previously reported mRNA gene profiling dataset [15] to identify mRNAs that were DE between the M1 and M5 subtypes (Table III).”
BackgroundMethodResultInfluentialAlonso, C. J., Sancho, Q. I. M., Simón-Hurtado, A., & Varela-Arrabal, R. (2012) · Expert Systems with Applications · doi:10.1016/j.eswa.2012.01.096 · Cited by 48
Expression and Prognosis Analyses of Runt-Related Transcription Factor Family in Human Leukemia
Sun, C., Li, S., Chen, Z., Li, G., Zhang, Q., & Li, D. (2018) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2018.12.008 · Cited by 48
Molecular cytogenetics in haematological malignancy: current technology and future prospects
Kearney, L., & Horsley, S. W. (2005) · Chromosoma · doi:10.1007/s00412-005-0002-z · Cited by 53
“largest study to use gene expression profiling found only 16 different distinct profiles (clusters), indicating that AML may not be as heterogeneous as previously thought, and that there may be just a few common pathways to the development of leukaemia (Valk et al. 2004).”
BackgroundFuchs, O., Provazníková, D., Kocova, M., Kostečka, A., Cvekova, P., Neuwirtová, R., Kobylka, P., Čermák, J., Březinová, J., Schwarz, J., et al. (2008) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2007.11.005 · Cited by 48
Reikvam, H., Hatfield, K. J., Lassalle, P., Kittang, A. O., Ersvær, E., & Bruserud, Ø. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903485659 · Cited by 49
“Acute myeloid leukaemia (AML) is a heterogeneous and aggressive disorder with diverse genetic abnormalities [1,2].”
BackgroundBrown, A. L., Wilkinson, C. R., Waterman, S. R., Kok, C. H., Salerno, D. G., Diakiw, S. M., Reynolds, B., Scott, H. S., Tsykin, A., Glonek, G. F. V., et al. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0206112 · Cited by 53
“[51]) Most common abnormality Genes down-regulated in V449E (Table 4)”
BackgroundResultKonantz, M., Andre, M. C., Ebinger, M., Grauer, M., Wang, H., Grzywna, S., Rothfuss, O. C., Lehle, S., Kustikova, O. S., Salih, H. R., et al. (2012) · Leukemia · doi:10.1038/leu.2012.211 · Cited by 48
Verhagen, H. J. M. P., Smit, M. A., Rutten, A. P., Denkers, F., Poddighe, P. J., Merle, P. A., Ossenkoppele, G. J., & Smit, L. (2015) · Blood · doi:10.1182/blood-2015-07-653840 · Cited by 47
“Acute myeloid leukemia (AML) is a heterogeneous disease that can be classified based on morphology, immunophenotypic features, and, more importantly, cytogenetic aberrations, molecular abnormalities, gene expression, andmethylation signatures.(1-3) Aberrant expression of the transcriptional regulator ecotropic viral i…”
BackgroundHaferlach, T., Kohlmann, A., Schnittger, S., Dugas, M., Hiddemann, W., Kern, W., & Schoch, C. (2005) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20175 · Cited by 47
“It was further published recently that subdiscrimination in AML focusing on molecular markers such as FLT3-LM or CEPBA (Valk et al., 2004) and on prognostication in patients with normal karyotypes also seemed possible on the basis of specific gene expression profiles (Yagi et al.”
BackgroundInfluentialGene Expression Profiling in Pulmonary Hypertension
Bull, T., Coldren, C. D., Geraci, M. W., & Voelkel, N. F. (2007) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200605-128jg · Cited by 47
“The strategy of gene expression as a biomarker has been successfully demonstrated in acute myeloid leukemia (17, 18).”
BackgroundMicroRNA expression in acute myeloid leukemia
Marcucci, G., Radmacher, M. D., Mrózek, K., & Bloomfield, C. D. (2009) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-009-0012-7 · Cited by 49
Identification of AML1-ETO modulators by chemical genomics
Corsello, S. M., Roti, G., Ross, K. N., Chow, K. T., Galinsky, I. A., DeAngelo, D. J., Stone, R. M., Kung, A. L., Golub, T. R., & Stegmaier, K. (2009) · Blood · doi:10.1182/blood-2008-07-166090 · Cited by 50
Ferrell, P. B., Diggins, K. E., Polikowsky, H. G., Mohan, S. R., Seegmiller, A. C., & Irish, J. M. (2016) · PLOS ONE · doi:10.1371/journal.pone.0153207 · Cited by 45
Mendez, L., Posey, R. R., & Pandolfi, P. P. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01162 · Cited by 53
de Jonge, H. J. M., de Bont, E. S. J. M., Valk, P. J. M., Schuringa, J. J., Kies, M. P., Woolthuis, C. M., Delwel, R., Veeger, N. J. G. M., Vellenga, E., Löwenberg, B., et al. (2009) · Blood · doi:10.1182/blood-2009-03-212688 · Cited by 51
“Platelets ( 109/L) 56 (3-998) 44* (3-339) 55* (5-998) 66* (8-722)”
Self-citationField, L. A., Jordan, R. M., Hadix, J. A., Dunn, M. A., Shriver, C. D., Ellsworth, R. E., & Ellsworth, D. L. (2007) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2007.01.004 · Cited by 46
Stölzel, F., Steudel, C., Oelschlägel, U., Mohr, B., Koch, S., Ehninger, G., & Thiede, C. (2010) · Annals of Hematology · doi:10.1007/s00277-009-0889-1 · Cited by 52
Kim, K., Baird, K., Davis, S. R., Piloto, O., Levis, M. J., Li, L., Chen, P., Meltzer, P. S., & Small, D. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06696.x · Cited by 46
“…similar genes in the gene set that also appear to be differentially expressed in previous microarray studies of AML primary samples (Ross et al, 2004; Valk et al, 2004). ª 2007 The Authors Journal Compilation ª 2007 Blackwell Publishing Ltd, British Journal of Haematology, 138, 603–615 615”
BackgroundResultVey, N., Mozziconacci, J., Groulet-Martinec, A., Debono, S., Finetti, P., Carbuccia, N., Beillard, E. J., Devilard, E., Arnoulet, C., Coso, D., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207910 · Cited by 46
“Some of these reports focused on the stratification of NC-AML (Debernardi et al., 2003; Kohlmann et al., 2003; Bullinger et al., 2004; Valk et al., 2004).”
BackgroundResultInfluentialKhandanpour, C., Krongold, J., Schütte, J., Bouwman, F. C. M., Vaßen, L., Gaudreau, M., Chen, R., Calero‐Nieto, F. J., Diamanti, E., Hannah, R., et al. (2012) · Blood · doi:10.1182/blood-2011-02-334722 · Cited by 53
Self-citationYe, Y., McDevitt, M. A., Guo, M., Zhang, W., Galm, O., Gore, S. D., Karp, J. E., Maciejewski, J. P., Kowalski, J., Tsai, H., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1153 · Cited by 49
“To further investigate CTNNA1 as a primary target of inactivation on 5q, published microarray expression data from primary AML cases was examined (25).”
HIF factors cooperate with PML‐RARα to promote acute promyelocytic leukemia progression and relapse
Coltella, N., Percio, S., Valsecchi, R., Cuttano, R., Guarnerio, J., Ponzoni, M., Pandolfi, P. P., Melillo, G., Pattini, L., & Bernardi, R. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201303065 · Cited by 47
“We used the publicly available datasets GSE1729 (Gutierrez et al , 2005), GSE1159 (Valk et al , 2004) and GSE19556 (Theilgaard-Monch et al , 2005) from the NIH Gene Expression Omnibus repository to select mRNA expression data of APL BM samples ( n = 25) and normal promyelocytes ( n = 3).”
Morris, V., Cummings, C. L., Korb, B., Boaglio, S. M., & Oehler, V. G. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00712-15 · Cited by 46
“Gene expression of KLF4 (A) and KLF2 (B) measured using the Affymetrix HU-133A microarray platform is from previously published data sets (33, 34).”
BackgroundMethodDirect Transcriptional Consequences of Somatic Mutation in Breast Cancer
Shlien, A., Raine, K. M., Fuligni, F., Arnold, R. R., Nik‐Zainal, S., Dronov, S., Mamanova, L., Rosic, A., Ju, Y. S., Cooke, S. L., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.07.028 · Cited by 47
Transposable Element Expression in Acute Myeloid Leukemia Transcriptome and Prognosis
Colombo, A., Triche, T. J., & Ramsingh, G. (2018) · Scientific Reports · doi:10.1038/s41598-018-34189-x · Cited by 45
Palande, K. K., Beekman, R., van der Meeren, L. E., Beverloo, H. B., Valk, P. J. M., & Touw, I. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016340 · Cited by 47
“Preparation of leukemia cell samples has been described previously [24].”
Self-citationGene expression profiling in acute myeloid leukemia
Valk, P. J. M., Delwel, R., & Löwenberg, B. (2004) · Current Opinion in Hematology · doi:10.1097/01.moh.0000149610.14438.9a · Cited by 45
Self-citationGFI1 as a novel prognostic and therapeutic factor for AML/MDS
Hönes, J. M., Botezatu, L., Helness, A., Vadnais, C., Vaßen, L., Robert, F., Hergenhan, S. M., Thivakaran, A., Schütte, J., Al-Matary, Y. S., et al. (2016) · Leukemia · doi:10.1038/leu.2016.11 · Cited by 52
Paz‐Priel, I., Houng, S., Dooher, J. E., & Friedman, A. D. (2011) · Blood · doi:10.1182/blood-2010-07-294470 · Cited by 50
A quantitative analysis of heterogeneities and hallmarks in acute myelogenous leukaemia
Hu, C. W., Qiu, Y., Ligeralde, A., Raybon, A. Y., Yoo, S., Coombes, K. R., Qutub, A. A., & Kornblau, S. M. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0387-2 · Cited by 46
Angenendt, L., Bormann, E., Pabst, C., Alla, V., Görlich, D., Braun, L. F., Dohlich, K., Schwöppe, C., Bohlander, S. K., Arteaga, M. F., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0505-x · Cited by 53
Self-citationVandewalle, V., Essaghir, A., Bollaert, E., Lenglez, S., Graux, C., Schoemans, H. M., Saussoy, P., Michaux, L., Valk, P. J. M., Demoulin, J., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16110 · Cited by 44
Self-citationGatekeeper function of the RUNX1 transcription factor in acute leukemia
Niebuhr, B., Fischer, M., Täger, M., Cammenga, J., & Stocking, C. (2007) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2007.07.018 · Cited by 48
ANP32A regulates histone H3 acetylation and promotes leukemogenesis
Yang, X., Lu, B., Sun, X., Han, C., Fu, C., Xu, K., Wang, M., Li, D., Chen, Z., Opal, P., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0010-7 · Cited by 47
Oligomerization of Evi-1 regulated by the PR domain contributes to recruitment of corepressor CtBP
Nitta, E., Izutsu, K., Yamaguchi, Y., Imai, Y., Ogawa, S., Chiba, S., Kurokawa, M., & Hirai, H. (2005) · Oncogene · doi:10.1038/sj.onc.1208754 · Cited by 44
“Recent studies have shown that elevated expression of Evi-1a in acute myelocytic leukemia (AML), which occurs in approximately 10% of the cases, is associated with unfavorable outcomes (Barjesteh van Waalwijk van Doorn-Khosrovani et al., 2003; Valk et al., 2004).”
BackgroundSato, T., Goyama, S., Kataoka, K., Nasu, R., Tsuruta-Kishino, T., Kagoya, Y., Nukina, A., Kumagai, K., Kubota, N., Nakagawa, M. M., et al. (2014) · Oncogene · doi:10.1038/onc.2014.108 · Cited by 46
The discovery and application of gene fusions in prostate cancer
Morris, D. S., Tomlins, S. A., Montie, J. E., & Chinnaiyan, A. M. (2008) · British Journal of Urology · doi:10.1111/j.1464-410x.2008.07665.x · Cited by 50
Frequent loss of RAF kinase inhibitor protein expression in acute myeloid leukemia
Zebisch, A., Wölfler, A., Fried, I., Wolf, O., Lind, K., Bodner, C., Haller, M., Drasche, A., Pirkebner, D., Matallanas, D., et al. (2012) · Leukemia · doi:10.1038/leu.2012.61 · Cited by 45
Self-citationExpression analysis of psychological stress-associated genes in peripheral blood leukocytes
Morita, K., Saito, T., Ohta, M., Ohmori, T., Kawai, K., Teshima-Kondo, S., & Rokutan, K. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.01.081 · Cited by 50
Tribbles-1 and -2 are tumour suppressors, down-regulated in human acute myeloid leukaemia
Gilby, D. C., Sung, H. Y., Winship, P. R., Goodeve, A. C., Reilly, J. T., & Kiss‐Toth, E. (2009) · Immunology Letters · doi:10.1016/j.imlet.2009.12.007 · Cited by 46
Schmidt, M., Möck, A., Jungk, C., Sahm, F., Ull, A. T., Warta, R., Lamszus, K., Gousias, K., Ketter, R., Roesch, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7396 · Cited by 43
Obesity and Leukemia: Biological Mechanisms, Perspectives, and Challenges
Tsilingiris, D., Vallianou, N. G., Spyrou, N., Kounatidis, D. C., Christodoulatos, G. S., Karampela, Ι., & Dalamaga, Μ. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00542-z · Cited by 50
“In AML, ERβ is more highly expressed than ERα in some AML patient gene sets [176, 177].”
BackgroundTranscriptional targeting by microRNA-Polycomb complexes: A novel route in cell fate determination
Zardo, G., Ciolfi, A., Vian, L., Billi, M., Racanicchi, S., Grignani, F., & Nervi, C. (2012) · Cell Cycle · doi:10.4161/cc.21468 · Cited by 45
Hes1 suppresses acute myeloid leukemia development through FLT3 repression
Kato, T., Sakata‐Yanagimoto, M., Nishikii, H., Ueno, M., Miyake, Y., Yokoyama, Y., Asabe, Y., Kamada, Y., Muto, H., Obara, N., et al. (2014) · Leukemia · doi:10.1038/leu.2014.281 · Cited by 44
HSC commitment–associated epigenetic signature is prognostic in acute myeloid leukemia
Bartholdy, B., Christopeit, M., Will, B., Mo, Y., Barreyro, L., Yu, Y., Bhagat, T. D., Okoye-Okafor, U. C., Todorova, T. I., Greally, J. M., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71264 · Cited by 43
“(G and H) Analysis of a third independent cohort of AML patients (39, 40).”
Increased DNA methylation of Dnmt3b targets impairs leukemogenesis
Schulze, I., Rohde, C., Scheller, M., Bäumer, N., Krause, A., Herbst, F., Riemke, P., Hebestreit, K., Tschanter, P., Lin, Q., et al. (2016) · Blood · doi:10.1182/blood-2015-07-655928 · Cited by 47
“Several studies described higher expression of Dnmt3b in AML samples when compared with healthy controls,(43,44) whereas others did not showa significant difference.(45,46) ComparedwithHSCs,DNMT3B expression was decreased in primary AML blasts (supplemental Figure 1A).”
ResultEstrogen Receptor β Is a Novel Target in Acute Myeloid Leukemia
Rota, S.-G., Roma, A., Dude, I., Ma, C., Stevens, R., MacEachern, J., Graczyk, J., Espiritu, S. M. G., Rao, P. P. N., Minden, M. D., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0292 · Cited by 44
Insights into the molecular profiles of adult and paediatric acute myeloid leukaemia
Aung, M. M. K., Mills, M. L., Bittencourt‐Silvestre, J., & Keeshan, K. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12899 · Cited by 57
“Associated with specific genetic subgroups are distinct transcriptional states [42], and in this report, we will highlight transcriptional profiling in paediatric and adult AML.”
Li, L., Piloto, O., Kim, K., Ye, Z., Nguyen, H. B., Yu, X., Levis, M. J., Cheng, L., & Small, D. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06525.x · Cited by 46
“Gene expression profiling studies based on cell lines and primary cells carrying activated FLT3 mutations reveal a number of genes to be deregulated by the presence of FLT3/ITD (Valk et al, 2004; Kim et al, 2005).”
BackgroundCharacterizing disease states from topological properties of transcriptional regulatory networks
Tuck, D. P., Kluger, H. M., & Kluger, Y. (2006) · BMC Bioinformatics · doi:10.1186/1471-2105-7-236 · Cited by 52
“In the first group we studied the following two-class datasets: a) acute lymphoblastic leukemia versus acute myeloid leukemia [23], b) two different myeloid leukemia types defined by the presence of two oncogeneic fusion proteins (AML1-ETO, t(8;21) versus RAR-PML, t(15;17)) [43].”
BackgroundMN1, a novel player in human AML
Grosveld, G. C. (2007) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2007.06.009 · Cited by 42
Loss of Dnmt3b accelerates MLL-AF9 leukemia progression
Zheng, Y., Zhang, H., Wang, Y., Li, X., Lu, P., Dong, F., Pang, Y., Ma, S., Cheng, H., Hao, S., et al. (2016) · Leukemia · doi:10.1038/leu.2016.112 · Cited by 43
Zhang, T., Yang, J., Vaikari, V. P., Beckford, J., Wu, S. K., Akhtari, M., & Alachkar, H. (2020) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-19-0077 · Cited by 51
“S1E, TCGA, 2.0-fold, P < 0.0001; GSE1159, 2.7-fold, P = 0.004).”
MethodInfluentialKirby, J., Heath, P. R., Shaw, P. J., & Hamdy, F. C. (2007) · Advances in clinical chemistry · doi:10.1016/s0065-2423(07)44008-2 · Cited by 47
Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes
Hernández‐Rivas, J. M., Castilla‐Llorente, C., Gutierrez, N. C., Isidro, I. M., Delgado, M., Rivas, J. D. L., Fermiñán, E., García, J. L., Ocio, E. M., del Cañizo, M. C., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403753 · Cited by 41
Expression profiling of leukemia patients: Key lessons and future directions
Shivarov, V. S., & Bullinger, L. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2014.04.006 · Cited by 44
Thol, F. R., Yun, H., Sonntag, A.-K., Damm, F., Weissinger, E. M., Krauter, J., Wagner, K., Morgan, M. A., Wichmann, M., Göhring, G., et al. (2012) · Annals of Hematology · doi:10.1007/s00277-012-1457-7 · Cited by 40
“Additionally, EVI1-expressing patients showed high MN1 and BAALC expression [22].”
BackgroundSTAT3 as a possible therapeutic target in human malignancies: lessons from acute myeloid leukemia
Bruserud, Ø., Nepstad, I., Hauge, M., Hatfield, K. J., & Reikvam, H. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2015.971005 · Cited by 41
Evi-1 as a critical regulator of leukemic cells
Goyama, S., & Kurokawa, M. (2010) · International Journal of Hematology · doi:10.1007/s12185-010-0618-5 · Cited by 40
“occurs in approximately 10% of cases of AML, defines a distinct subtype of AML [7].”
BackgroundPathogenetic significance of ecotropic viral integration site‐1 in hematological malignancies
Goyama, S., & Kurokawa, M. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01152.x · Cited by 40
Commonly dysregulated genes in murine APL cells
Yuan, W., Payton, J. E., Holt, M. S., Link, D. C., Watson, M. A., DiPersio, J. F., & Ley, T. J. (2006) · Blood · doi:10.1182/blood-2006-07-036640 · Cited by 43
Patterns of TPD52 overexpression in multiple human solid tumor types analyzed by quantitative PCR
Tennstedt, P., Bölch, C., Strobel, G., Minner, S. J. P., Burkhardt, L., Grob, T. J., Masser, S., Sauter, G., Schlomm, T., & Simon, R. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2200 · Cited by 41
Molecular assessment of depression from mRNAs in the peripheral leukocytes
Iga, J., Ueno, S., & Ohmori, T. (2008) · Annals of Medicine · doi:10.1080/07853890802082088 · Cited by 44
A Noncanonical Flt3ITD/NF-κB Signaling Pathway Represses DAPK1 in Acute Myeloid Leukemia
Shanmugam, R., Gade, P., Wilson-Weekes, A., Sayar, H., Suvannasankha, A., Goswami, C. P., Li, L., Gupta, S. K., Cardoso, A. A., Baghdadi, T. A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3022 · Cited by 44
Azuaje, F. J., Devaux, Y., & Wagner, D. R. (2010) · BMC Systems Biology · doi:10.1186/1752-0509-4-60 · Cited by 47
“However, several studies have demonstrated the usefulness of blood cell transcriptomes to identify biomarkers in both the oncology [48,49] and cardiovascular fields [50].”
BackgroundBeekman, R., Valkhof, M. G., van Strien, P., Valk, P. J. M., & Touw, I. P. (2013) · Haematologica · doi:10.3324/haematol.2013.085050 · Cited by 39
Self-citationNagy, Á. M., Ősz, Á., Budczies, J., Krizsán, S., Szombath, G., Demeter, J., Bödör, C., & Győrffy, B. (2019) · Journal of Advanced Research · doi:10.1016/j.jare.2019.05.006 · Cited by 49
“The GSE1159 dataset [37] includes 293 patients measured using Affymetrix Human Genome U133A Arrays (GPL96).”
MethodShi, J., Fu, L. N., & Wang, W. (2015) · Oncotarget · doi:10.18632/oncotarget.3024 · Cited by 39
“All samples were collected at diagnosis, with bone marrow aspirates or peripheral-blood, containing 80–100 percent blast cells after thawing [29].”
MethodLeukemia targeting ligands isolated from phage display peptide libraries
Jäger, S., Jahnke, A., Wilmes, T., Adebahr, S., Vögtle, F. ‐., deLima-Hahn, E., Pfeifer, D., Berg, T., Lübbert, M., & Trepel, M. (2007) · Leukemia · doi:10.1038/sj.leu.2404548 · Cited by 45
Pattern robustness of diagnostic gene expression signatures in leukemia
Kohlmann, A., Schoch, C., Dugas, M., Rauhut, S., Weninger, F. J., Schnittger, S., Kern, W., & Haferlach, T. (2004) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20126 · Cited by 39
“…in routine clinical procedures, both for the initial diagnosis of a disease and for determining prognosis (Alizadeh et al., 2000; Ramaswamy et al., 2001, 2003; Van De Vijver et al., 2002; Yeoh et al., 2002; Staudt, 2003; Wright et al., 2003; Bullinger et al., 2004; Garber, 2004; Valk et al., 2004).”
BackgroundMethodUnderground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells
Dulphy, N., Chrétien, A.-S., Khaznadar, Z., Fauriat, C., Nanbakhsh, A., Caignard, A., Chouaïb, S., Olive, D., & Toubert, A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00094 · Cited by 44
Wouters, B. J., Louwers, I., Valk, P. J. M., Löwenberg, B., & Delwel, R. (2007) · Blood · doi:10.1182/blood-2006-08-042325 · Cited by 39
Self-citationSakhinia, E., Faranghpour, M., Yin, J. A. L., Brady, G., Hoyland, J. A., & Byers, R. J. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05594.x · Cited by 39
“There have since been several other studies identifying prognostic gene sets in acute leukaemia (Bullinger et al, 2004; Cole et al, 2004; Court et al, 2004; Valk et al, 2004) and many for other cancers (Greer & Khan, 2004).”
ResultGene-Expression Profiling in Acute Myeloid Leukemia
Grimwade, D. J., & Haferlach, T. (2004) · New England Journal of Medicine · doi:10.1056/nejme048040 · Cited by 39
Fortier, J. M., Payton, J. E., Cahan, P., Ley, T. J., Walter, M. J., & Graubert, T. A. (2010) · Leukemia · doi:10.1038/leu.2010.61 · Cited by 48
“These studies have also demonstrated that the POU4F1 gene is consistently dysregulated in t(8;21) human patient samples (9, 10).”
InfluentialCabezas‐Wallscheid, N., Eichwald, V., de Graaf, J., Löwer, M., Lehr, H., Kreft, A., Eshkind, L. G., Hildebrandt, A., Abassi, Y., Heck, R., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302661 · Cited by 44
“In these studies, transcriptional AE target genes and epigenetic modi fi cations were identi fi ed that link AE function to cellular proliferation, self ‐ renewal and differentiation (Alcalay et al, 2003; Balgobind et al, 2011; Kvinlaug et al, 2011; Ptasinska et al, 2012; Ross et al, 2004; Valk et al, 2004).”
InfluentialThe CINSARC signature as a prognostic marker for clinical outcome in multiple neoplasms
Lesluyes, T., Delespaul, L., Coindre, J., & Chibon, F. (2017) · Scientific Reports · doi:10.1038/s41598-017-05726-x · Cited by 40
Bruserud, Ø., Aasebø, E., Hernandez-Valladares, M., Tsykunova, G., & Reikvam, H. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1356818 · Cited by 39
Clinical significance of Gata‐1, Gata‐2, EKLF, and c‐MPL expression in acute myeloid leukemia
Ayala, R. M., Martínez‐López, J., Albízua, E., Díez, A., & Gilsanz, F. (2008) · American Journal of Hematology · doi:10.1002/ajh.21332 · Cited by 43
Enquobahrie, D. A., Williams, M. A., Qiu, C., Muhie, S. Y., Slentz‐Kesler, K., Ge, Z., & Sorenson, T. (2009) · BMC Pregnancy and Childbirth · doi:10.1186/1471-2393-9-56 · Cited by 38
Possibilities for tailored and targeted therapy in paediatric acute myeloid leukaemia
Zwaan, C. M., & Kaspers, G. J. L. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05167.x · Cited by 38
“Some of these subgroups were defined by well-known cytogenetic abnormalities, but in addition several new groups were identified (Valk et al, 2004).”
BackgroundPHARMACOGENOMICS OF ACUTE LEUKEMIA
Cheok, M. H.-C., Lugthart, S., & Evans, W. E. (2006) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.100018 · Cited by 38
Dunphy, C. H. (2006) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2006-130-483-gepdil · Cited by 42
Metadata
- Authors
- Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., & Delwel, R.
- Affiliations
- Erasmus MC (NL)
- Leiden University Medical Center (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-04-15
- Volume
- 350
- Issue
- 16
- Pages
- 1617-1628
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2110502951
- Cited by
- 1,370
- References
- 30
- Citations by year
- 2026: 8 · 2025: 22 · 2024: 27 · 2023: 40 · 2022: 30 · 2021: 59 · 2020: 49 · 2019: 50 · 2018: 40 · 2017: 39 · 2016: 66 · 2015: 53 · 2014: 64 · 2013: 72 · 2012: 86
- FWCI
- 63.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Funders
- Erasmus Medisch Centrum
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- acute myeloid leukemia, gene expression profiling, prognostic stratification, molecular signatures, patient clustering, inv(16), CEBPA mutation, chromosomal abnormalities, normal karyotype, treatment outcomes
- MeSH terms
- Acute Disease, Adult, Algorithms, Chromosome Aberrations, Female, Humans, Karyotyping, Leukemia, Myeloid, Male, Middle Aged, Mutation, Prognosis, Software, Gene Expression, Multivariate Analysis, Cluster Analysis, Survival Analysis, Oligonucleotide Array Sequence Analysis, Cytogenetic Analysis, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.